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M A T E R I A L S  S C I E N C E
Peptide-protein coassembling matrices as a biomimetic 
3D model of ovarian cancer
Clara Louise Hedegaard1,2, Carlos Redondo-Gómez1,2, Bee Yi Tan3, Kee Woei Ng3,4,5,6, 
Daniela Loessner7,8,9, Alvaro Mata1,2,10,11,12*
Bioengineered three-dimensional (3D) matrices expand our experimental repertoire to study tumor growth 
and progression in a biologically relevant, yet controlled, manner. Here, we used peptide amphiphiles (PAs) to 
coassemble with and organize extracellular matrix (ECM) proteins producing tunable 3D models of the tumor 
microenvironment. The matrix was designed to mimic physical and biomolecular features of tumors present in 
patients. We included specific epitopes, PA nanofibers, and ECM macromolecules for the 3D culture of human 
ovarian cancer, endothelial, and mesenchymal stem cells. The multicellular constructs supported the formation of 
tumor spheroids with extensive F-actin networks surrounding the spheroids, enabling cell-cell communication, 
and comparative cell-matrix interactions and encapsulation response to those observed in Matrigel. We conducted 
a proof-of-concept study with clinically used chemotherapeutics to validate the functionality of the multicellular 
constructs. Our study demonstrates that peptide-protein coassembling matrices serve as a defined model of the 
multicellular tumor microenvironment of primary ovarian tumors.
INTRODUCTION
There is a need for improved three-dimensional (3D) cancer models 
to study tumor growth and progression as seen in patients and to 
test responses to new treatments. At present, 90% of successful cancer 
treatments tested preclinically fail in the early phases of clinical trials, 
and less than 5% of oncology drugs are successful in clinical trials 
(1). Preclinical tests rely on a combination of 2D in vitro cell cultures 
and in vivo models to predict responses to treatment. Conventional 
2D cell cultures fail to recapitulate key features of tumor tissues, such 
as cellular heterogeneity, presence of spheroids, matrix stiffness, 
cell-matrix interactions, and cross-talk with other cell types (2). On 
the other hand, murine models allow for cell-matrix and cell-cell 
interactions, but interspecies differences result in many successful 
treatments in murine hosts being ineffective in humans. Thus, novel 
experimental 3D cancer models are needed to better recapitulate the 
human tumor microenvironment (TME) and incorporate patient- 
specific differences.
The TME is a rich mixture of malignant and nonmalignant cells, 
such as fibroblasts, endothelial cells, and immune cells, embedded in 
an extracellular matrix (ECM) (3). The TME affects tumor growth 
and undergoes changes in response to cancer progression, such as 
stiffening of the ECM, shifts in chemical signaling, and tumor 
angiogenesis (4). Tumor angiogenesis arises when the tumor core 
undergoes hypoxia and triggers the secretion of proangiogenic pro-
teins and the migration of endothelial cells toward the tumor. The 
resulting vessels are leaky and disorganized, consequently influencing 
the components of the TME. Collectively, these changes in the local 
microenvironment affect both cancer progression and responses to 
treatments. Thus, modeling the TME is vital and must recapitulate 
cell-cell and cell-matrix interactions as well as key components of 
the ECM, such as proteins, growth factors (GFs), and chemical gra-
dients. Furthermore, the model should integrate multiple cell types 
that enable the growth of tumor spheroids.
Currently, the gold standard for 3D cancer models is the com-
mercially available Matrigel (5), a solubilized basement membrane 
extracted from mouse sarcoma that consists of an undefined mix-
ture of ECM proteins and GFs. A major reason for Matrigel’s popu-
larity is its capacity to enable cell-matrix interactions, which promote 
the growth of malignant and nonmalignant cells as well as spheroid 
formation (6). However, it lacks control in mimicking the TME be-
cause of its high batch variability, undefined composition, and 
murine origin. These features are important limitations to effectively 
screen and develop new treatments for cancer. To address these 
drawbacks, natural and synthetic materials are being explored as 
alternatives to generate 3D cancer models, such as hyaluronic acid 
hydrogels (7), chitosan/gelatin composites (8), and polyethylene glycol 
(PEG) (9). Natural materials recapitulate structural aspects of the 
ECM, but they exhibit limited control over their mechanical prop-
erties. While synthetic materials can overcome the limitations in 
mechanical control, the trade-off is bioactivity. Thus, hybrid systems, 
such as PEG modified with fibrinogen (10), heparin (11), isoleucine- 
lysine-valine-alanine-valine (IKVAV) or arginine-glycine-aspartate 
(RGD) peptides (12), are being studied. However, while these com-
posites greatly improve cellular responses, they do not capture the 
fibrous ECM nanostructure and heterogeneous composition and tend 
to require the use of potentially cytotoxic cross-linking components.
Self-assembling peptide-based materials can be programmed to 
assemble into well-defined nanostructures, such as micelles, nano-
fibers, or ribbons, while generating porosity and displaying multiple 
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bioactive epitopes (13). These materials have been optimized to en-
hance their capacity to recreate the ECM, for example, by enabling 
alignment (14), tunability of mechanical properties (15), and the 
incorporation of protein-mimetic sequences to promote angiogenesis 
(16). Peptide amphiphiles (PAs) are promising self-assembling ma-
terials, which are capable of assembling into well-defined nanofibers 
(17) with the capacity to display cell-instructive motifs that mimic 
ECM proteins or GFs, such as laminin, collagens, and fibronectin 
(FN) (18). This approach is increasingly being used to coassemble 
peptides with a variety of molecules, such as hyaluronic acid (19), 
heparin (20), and proteins (21, 22), to develop biologically relevant 
3D cell cultures.
Here, we report the design and validation of a peptide-protein 
coassembling hydrogel-based multicellular 3D model for ovarian 
cancer. We demonstrate the capacity of the system to serve as a com-
plex, yet controllable, alternative to Matrigel. The hydrogel supported 
the spheroid formation from single ovarian cancer cells reaching com-
parative sizes to those grown in Matrigel. When cocultured with 
human umbilical vein endothelial cells (HUVECs) and human 
mesenchymal stem cells (hMSCs), the hydrogel enabled cellular in-
teractions between the different cell types. The model demonstrated 
an increase in spheroid size as a result of increased cell-cell interac-
tions. We also tested the effect of different peptide sequences and 
proteins within the multicomponent hydrogel, indicating the tun-
ability of the system. In a proof-of-concept study, we determined 
tumor cell responses to different chemotherapeutics.
RESULTS
Rationale of the design
The herein reported coassembling hydrogel is based on our recently 
developed PA/keratin (KN) bioink (22), which served as a supramolecular 
platform to incorporate and optimize structural, molecular, and 
cellular components of the TME of ovarian cancer (Fig. 1A). We syn-
thesized three new PA sequences based on the previously established 
PA-H (C16VVVAAAH2K), which includes an histidine-histidine-lysine 
(H2K) motif to facilitate coassembly with ECM proteins (22): PA-VH 
(C16VVVAAAVPGIGH2K), which contains an additional elastin- 
mimetic segment that enhances recreation of the ECM and was found 
to improve hydrogel stability; PA-RGDS (C16VVVAAAH2KRGDS), 
which incorporates an additional arginine-glycine-aspartic acid- 
serine (RGDS) sequence to promote cell adhesion; and PA-GHK 
(C16VVVAAAH2KGHK), which includes an additional glycine-histidine- 
lysine (GHK) motif known to promote cell proliferation and to serve 
as an angiogenic factor (Figs. 1B and 2A and fig. S1) (23). The PAs 
were designed to gel by coassembling with proteins through charge 
screening using the base PA (PA-H) as a control. We included FN, 
which is up-regulated in the ECM of the ovarian TME (24), and hair 
KN, which supports cell proliferation and tissue regeneration (25). Spe-
cific KNs are involved in the regulation of inflammation and immu-
nity in epithelial layers (26, 27). Furthermore, KN provides structural 
stability to tissues and is expressed in normal and cancerous ovaries 
(Fig. 2B) as well as in ovarian cancer cell monolayers (fig. S2A).
A range of PA/KN hydrogel formulations were used throughout 
this work (Fig. 1B). In material characterization studies and 3D 
monocultures, PA-VH was tested using PA-H as a control. In a pre-
vious study, we used both PA-H and PA-VK sequences, showing 
favorable results for PA-VK in terms of hydrogel strength and 
PA-H for cell interaction. Thus, here, we wanted to build on our 
previous work by designing the sequence PA-VH and keeping PA-H 
as control for the influence of “V” (22). The hydrophobic section V 
(= VPGIG) was taken from elastin and has been used as part of bio-
compatible and biodegradable elastin-like polypeptides (28). We 
expected V to facilitate self-assembly into fibers and stronger inter-
actions with KN. For 3D tricultures, PA-VH was mixed with PA-RGDS 
or PA-GHK at 10:1 (vol/vol) ratios before coassembly with the pro-
teins. The rational here was to use the PA’s ability to coassemble 
between different PA molecules and present epitopes on the fiber 
surfaces. The PA ratio was selected to optimize the presentation and 
cellular recognition of the bioactive epitopes of PA-RGDS and 
PA-GHK. Previous studies have shown that epitope recognition can 
be maximized by spacing them within PA fibers (29). Last, in addi-
tion to the incorporation of multiple proteins and bioactive epitopes, 
the coassembling hydrogel was designed for encapsulation of three 
major cell types of the ovarian TME, including epithelial cancer cells, 
HUVECs, and hMSCs.
Hydrogel formation and characterization at the  
nano- and macroscale
Hydrogels were formed upon mixing PAs with the ECM proteins 
by injecting 15 l of PA solution (10 mg/ml ± cells) into 100 l of 
protein solution (10 mg/ml ± cells). PAs were synthesized as previously 
described (30), and their assembly assessed via circular dichroism 
(CD) and transmission electron microscopy (TEM). We found that 
all individual PAs and their mixtures exhibited the characteristic 
 sheet secondary structure (fig. S3A) and the classical nanofibrous 
architecture of self-assembled PAs (Fig. 2C and fig. S3C). The con-
trol sequence C16VVVAAAH2K of all tested PAs dictated that the 
inter-PA interaction mechanism and the different bioactive epitopes 
of the PAs did not interfere with the assembly process (fig. S3B). 
This result was further confirmed by TEM, which revealed that the 
PA-VH/KN coassembled nanofibers exhibited similar morphologies 
as those formed by the control PA-H/KN, as previously reported 
(Fig. 2D and fig. S3, C to E) (22). In addition, upon PA-protein co-
assembly, hydrogels formed immediately and exhibited a translucent 
appearance that did not appear to change 30 min after coassembly, 
at which point they were easily handled (Fig. 2E). However, PA-based 
hydrogels, like many self-assembling hydrogels, are fragile structures 
that can be difficult to manipulate without altering their macroscopic 
shape, despite retaining their inherent nanofibrous architecture 
(Fig. 2E). The moldability of this nanofibrous network (i.e., ability 
to expand, contract, and shift) is an important feature for cell en-
capsulation, creating a porous interactive structure. These character-
istics facilitate cell migration, cell-cell communication, and spheroid 
growth, which are critical to recreate the TME. Nonetheless, the 
structural integrity of self-assembling hydrogels can be a limiting 
factor. To improve on this, our PA-protein coassembling strategy is 
expected to enhance stability over PA hydrogels and enable higher 
control over their stiffness (e.g., by varying PA sequences, PA-protein 
affinities, and PA and protein concentrations), as explored in the 
subsequent two sections.
Hydrogel stiffness characterization
Ovarian cancer spheroids are highly dependent on matrix stiffness 
(24). While soft hydrogels [storage modulus (G′) ~ 0.5 kPa] lead to 
loose cell aggregation, stiff hydrogels (G′ ≥ 7 kPa) inhibit cell pro-
liferation, leading to smaller inhomogeneously shaped spheroids 
with decreased metabolic activity (31). A similar stiffness dependence 
 o
n
 O
ctober 5, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Hedegaard et al., Sci. Adv. 2020; 6 : eabb3298     2 October 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
3 of 15
is reported for prostate cancer spheroids (32). We tested the hydrogel 
stiffness by rheometry on acellular PA-VH/KN hydrogels (prepared 
as described in the “Hydrogel formation and characterization at the 
nano- and macroscale” section) in either cell culture medium or 10 mM 
HEPES after 24 hours in comparison to the control hydrogel PA-H/KN. 
Culture medium was used to assess the behavior of the hydrogels 
during cell cultures, while HEPES served as control.
In HEPES, no significant stiffness differences were observed be-
tween PA-VH/KN (G′ = 1616 ± 198 Pa) and the control PA-H/KN 
(G′ = 1965 ± 633 Pa) hydrogels (Fig. 2F). Comparing PA-VH/KN 
hydrogels in culture medium and in HEPES, a significant increase 
in stiffness was observed for hydrogels in medium (G′ = 2133 ± 111 Pa, 
P < 0.05; fig. S4A). When leaving the PA-VH/KN hydrogels for 15 days 
in culture medium, a further increase (G′ = 2633 ± 633 Pa) was ob-
served compared to the 24-hour time point, although not statistically 
significant (fig. S4A). This kind of culture medium–induced increase 
in hydrogel stiffness has been reported (33). Overall, our findings show 
that the coassembling hydrogels are within the optimal stiffness range 
Fig. 1. Peptide/protein coassembling hydrogel for 3D cancer models. (A) Schematic of the peptide/protein coassembling hydrogel with key design features high-
lighted and an illustration of the process of cell encapsulation within the hydrogel. The hydrogel is made using solutions of PAs and a protein mixture [e.g., keratin (KN) 
and FN]. Cells are suspended in the PA solution leading to encapsulation. Cell-containing hydrogels are monitored over several weeks to observe cell-cell and cell-matrix 
patterns, cell growth, and drug response. (B) Table of the PA/KN hydrogel combinations used for the material analysis (see the “Hydrogel formation and characterization 
at the nano- and macroscale,” “Hydrogel stiffness characterization,” and “Hydrogel stability characterization” sections in Results), 3D monocultures (see the “Cell monocultures 
within PA/KN hydrogels generate tumor spheroids” section in Results), stromal-cell viability study (see the “PA/KN hydrogels support 3D monocultures of HUVECs and 
hMSCs” section in Results), 3D tricultures (see the “3D cocultures of cancer cells with stromal cells in PA/KN hydrogels promote intercellular network formation” section in 
Results), and treatment study (see the “Responses to treatment in spheroid-containing PA/KN hydrogels” section in Results).
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(G′ > 0.5 kPa and < 7 kPa) reported to support tumor spheroid for-
mation from single-cell encapsulation (31).
Hydrogel stability characterization
Another critical parameter of the ECM is its capacity to degrade and 
to enable cell and spheroid growth (24). Peptide hydrogels are known 
to degrade enzymatically through peptide cleavage (34). Conversely, 
an ideal hydrogel needs to remain sufficiently stable for spheroid 
formation while enabling ECM secretion and remodeling (35, 36). 
We tested the hydrogel stability by incubating acellular PA-VH/KN 
hydrogels and control PA-H/KN hydrogels in cell diluents phosphate- 
buffered saline (PBS) and HEPES for 3 months at 37°C mimicking 
cell culture conditions. The hydrogel weight was monitored daily for 
the first week and subsequently weekly to assess degradation, with 
the data reported as the weight fraction (Mt) of the weight recorded 
at the start of the experiment (M0). Similar results were observed for 
Fig. 2. PA/KN hydrogel combinations and material analysis. (A) Table of PA sequences and proteins used in this study including the chemical formula, molecular 
weight (MW), concentration used, and zeta potential at pH 7.5 (*in HEPES (pH 7.5), **in water, ***relative to keratin volume, +theoretical). (B) Immunohistochemical (IHC) 
staining for keratin type I (KRT32) and type II (KRT82) in normal (healthy) ovary and ovarian cancer tissue samples, with IHC controls in fig. S2. (C) TEM image of self-assembled 
PA fibers (PA-VH) in HEPES [0.1 mg/ml (pH 7.5)]. (D) TEM image of PA fibers interacting with KN (PA-VH/KN). Pure solutions of PA-VH and KN in HEPES [0.1 mg/ml (pH 7.5)] 
were mixed in ratio 1:1 before analysis. (E) Photograph of a PA-H/KN hydrogel after 14 days in culture medium at 37°C and a representative scanning electron micros-
copy image of the internal heterogeneous nanofibrous structure of PA/KN hydrogels. (F) Rheological characterization of the hydrogels, measuring the storage modulus 
(G′) and loss modulus (G″) of PA-H/KN and PA-VH/KN hydrogels (mean ± SEM). (G) Graphical plot of the hydrogel mass (Mt/M0) against time, indicating the slow degra-
dation of PA-H/KN and PA-VH/KN hydrogels in PBS 1× at 37°C (mean ± SEM). Photo credit: Clara Hedegaard, Queen Mary University of London. ns, not significant.
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PBS (Fig. 2G) and HEPES (fig. S4B). For PA-VH/KN hydrogels in PBS, 
the first significant difference in weight compared to the starting 
weight (M0) was observed after 27 days (M27 = 0.75 ± 0.1 fraction of 
M0; Fig. 2G), with a weight fraction below 40% remaining after 
3 months (M92 = 0.35 ± 0.04 fraction of M0). Conversely, the control 
PA-H/KN hydrogels degraded comparatively faster. However, both 
hydrogels remained visibly present after 3 months despite the loss 
in mass (Fig. 2G). Previous studies have shown that spheroid for-
mation from single cancer cells occurs within ~2 weeks (9, 12, 37), 
indicating that the PA-VH/KN hydrogels are sufficiently stable to 
support spheroid formation. The discrepancy between the quantified 
weight loss and the unchanged hydrogel structure may be attributed 
to swelling effects of the hydrogels, with >90% water content (22). 
Overall, PA-VH/KN hydrogels exhibit a suitable level of degrada-
tion to enable ECM generation.
Cell monocultures within PA/KN hydrogels generate  
tumor spheroids
Next, we sought to determine whether the encapsulation of ovarian 
cancer cells leads to tumor spheroid formation from a single-cell 
suspension within PA-VH/KN hydrogels compared to cells grown 
within Matrigel. Spheroid formation occurred over 21 days in PA-
VH/KN hydrogels and Matrigel as detected by bright-field and 
fluorescence microscopy, with a higher spheroid density in Matrigel 
(Fig. 3, A and B, and fig. S5A) bright-field control of PA/KN. Assay-
ing the metabolic activity as an indicator of cell proliferation, we 
found that PA-VH/KN hydrogels follow the same trend as Matrigel 
over 21 days, albeit with slightly lower cell numbers (Fig. 3C). The 
readout fluorescence count for Matrigel rose to 7600 ± 2037, whereas 
the PA/KN ended at 2961 ± 491 after 21 days (readout fluorescence 
values in fig. S5C). Other studies have shown that Matrigel artificially 
increases the growth rate of tumor cells (38). However, extensive 
cell detachment and hydrogel fragmentation were observed in 
Matrigel cultures on days 14 to 21 (fig. S5B), which was not the case 
for PA-VH/KN hydrogels. This enhanced stability is also evident, 
for example, in the metabolic activity studies where we retained all 
replicate PA/KN hydrogels for 21 days, compared to a 40% loss for 
Matrigel. These results are in alignment with previous studies that 
have also reported on the poor mechanical properties of Matrigel 
(38). We speculate that this characteristic may result from the lim-
ited mechanical stability of Matrigel, leading to uncontrolled cell 
migration and matrix digestion and subsequent collagen-induced 
shrinkage.
To investigate these differences, scanning electron microscopy 
confirmed the more compact spheroid formation in PA-VH/KN 
hydrogels compared to Matrigel (Fig. 3D). In PA-VH/KN hydrogels, 
the typical cobblestone morphology of epithelial cancer cells was 
observed [Fig. 3D; (1)], with varying degrees of spheroid develop-
ment through continued proliferation and with defined cell-cell 
junctions. Cell-matrix interactions between cancer cells and the 
PA-VH/KN hydrogel were visible, exhibiting cell anchorage to the 
nanofibrous PA/KN network [Fig. 3D, (2)]. In addition, the spher-
oids in these hydrogels comprised surfaces covered in microvilli 
[Fig. 3D, (3)], which is characteristic of epithelial cancer cells and 
affects the sensitivity to cytotoxic compounds, such as chemo-
therapeutics (39). Comparatively, cells grown in Matrigel displayed 
both the cobblestone morphology and homogeneous spreading 
across cell aggregates (Fig. 3E). In the later stages of 3D cell cul-
ture (~day 21), individual spheroids were only distinguishable in 
PA-VH/KN hydrogels, suggesting less cell migration compared 
to Matrigel.
Further characterization was conducted by measuring the cross- 
sectional area of spheroids at several time points (days 1, 7, 14, and 
21) using PA-H/KN hydrogels as control. The average spheroid size 
in PA-VH/KN hydrogels at day 21 (10,862 ± 1929 m2; Fig. 3F) was 
comparable to those previously reported using prostate (11) and 
breast (12) cancer cells at day 14. Some spheroids grown within our 
PA-VH/KN hydrogels did reach similar sizes to those reported in 
the literature over 14 days in 3D cell culture. Spheroids formed from 
single cells and grew over time (Fig. 3F), with individual cancer cells 
giving way to larger spheroids leading to an overall reduced spheroid 
count at day 21 compared to day 1. Comparatively, PA-H/KN 
hydrogels led to smaller spheroids at day 21 (4623 ± 1002 m2) with 
a significant decrease in spheroid count across all time points tested 
(fig. S5D). PA-VH/KN hydrogels exhibited higher propensity for 
spheroid formation compared to PA-H/KN (Fig. 3G), which was 
confirmed by microscopy of both cell-containing PA/KN hydrogels 
over 21 days, with PA-VH/KN hydrogels supporting comparable 
spheroid growth and size to Matrigel (Fig. 3 and fig. S5E). These 
findings demonstrate the feasibility of PA/KN hydrogels in support-
ing tumor spheroid formation from single cells, with PA-VH/KN 
being favorable over PA-H/KN. Stable spheroid formation occurred 
in PA-KN hydrogels over 21 days, representing the key advantage 
over Matrigel-based 3D cell cultures.
PA/KN hydrogels support 3D monocultures of  
HUVECs and hMSCs
The ovarian TME contains not only malignant cells but also non-
malignant cells that support tumor survival and growth through 
processes like angiogenesis. As tumors grow, their cores become 
hypoxic, which, in turn, leads to the expression of proangiogenic 
proteins and GFs, such as vascular endothelial growth factor (VEGF) 
and fibroblast growth factor (FGF) (40). In previous 3D cocultures 
of HUVECs and cancer cells, HUVECs migrated toward the tumor 
spheroids (41). We sought to test the suitability of PA-VH/KN 
hydrogels to support the formation of capillary-like structures by 
encapsulating HUVECs and hMSCs. First, we explored the compat-
ibility of PA/KN hydrogels with each cell type. Encapsulation of 
either HUVECs or hMSCs in PA-VH/KN hydrogels showed a high 
viability of 85 and 75%, respectively, over 7 days (fig. S6, A and B). 
Thus, PA/KN hydrogels are suitable for multicellular cultures of 
malignant with nonmalignant cells.
Next, the propensity of HUVECs to form endothelial networks 
was explored by comparing 3D monocultures of HUVECs in PA-
VH/KN hydrogels to Matrigel. At day 2, limited cell spreading and 
networks were observed in cells grown within PA-VH/KN hydro-
gels. HUVECs in Matrigel seemed to form networks at the edges; 
however, these networks disappeared over time and were dissolved 
after day 5 (fig. S6C). Conversely, when HUVECs were instead seeded 
on top of PA-VH/PA-RGDS/KN hydrogels and Matrigel, they ad-
hered (Fig. 4A) and interacted with both matrices (fig. S6D). It was 
not possible to process Matrigel samples for immunostaining be-
cause of the gels disintegrating when immersed in paraformaldehyde 
(PFA), a well-documented issue (Fig. 4B) (6). Using PA-VH/PA-
RGDS/KN hydrogels, endothelial cell networks were formed 5 days 
after seeding (Fig. 4, A and B) and CD31 was detected on day 9 in 
proximity to tight junctions between the cells [Fig. 4, C (control) 
and D (sample)]. In comparison to the monolayer control, the CD31 
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staining of the hydrogels was relatively weak. Nonetheless, the network 
was confirmed by scanning electron microscopy, which depicted 
complete HUVEC coverage on top of the PA-VH/PA-RGDS/KN 
hydrogels (Fig. 4E). As with the encapsulation, networks did not re-
main intact and started to disappear with no CD31 staining evident 
after day 9. These results are in line with other studies reporting the 
formation of a HUVEC monolayer on collagen/chitosan hydrogels 
(42). Comparatively, cells grown on Matrigel aligned directionally 
to form tubular polygonal networks, which remained present for 
8 days (Fig. 4A and fig. S6E). The network was not verified beyond 
day 8, as previous studies have shown this timeline to be sufficient 
(12). Because of the difficulties in fixing Matrigel with PFA (5), we 
were unable to use these samples for immunofluorescent (IF) analysis. 
Thus, while neither matrix supported cell spreading in 3D, both 
matrices promoted adhesion and proliferation when cells were seeded 
on top.
Overall, our results demonstrate that, while PA/KN hydrogels 
support encapsulation of HUVECs, additional factors are needed 
to promote endothelial network structures within these hydrogels. 
Studies have indicated a role of hMSCs and ECM proteins, such as 
Fig. 3. Monoencapsulation of ovarian cancer cells in PA/KN hydrogels and Matrigel (500 cells/l gel). (A) Bright-field and Live (green)/Dead (red) images of ovarian 
cancer OVCAR-4 cells in PA-VH/KN hydrogels and Matrigel after 21 days of encapsulation. (B) Immunofluorescent (IF) images of F-actin network (phalloidin/red) and 
nuclei [4′,6-diamidino-2-phenylindole (DAPI)/blue] of ovarian cancer cells in PA-VH/KN hydrogels and Matrigel on day 21. (C) Comparison of the metabolic activity of 
ovarian cancer cells over time in PA-VH/KN hydrogels and Matrigel using an alamarBlue assay. The plot shows the values normalized to day 1 against time. (D) Scanning 
electron microscopy images of tumor spheroids grown within PA-VH/KN hydrogels on day 14. The images show the cobble structure of ovarian cancer and the anchoring 
points to the nanofibrous hydrogel matrix. (E) Scanning electron microscopy images of tumor spheroids grown in Matrigel on day 7, exhibiting comparative cobble 
structure. (F) IF images were used to measure the spheroid cross-sectional area (m2), shown here as a Gaussian distribution on days 1, 7, 14, and 21. The graphical plots 
reveal the shift from single cells at ~500 m2 to clusters up to 97,500 m2. (G) PA-H/KN and PA-VH/KN hydrogels were compared by plotting the size distribution of 
tumor spheroids at day 21, demonstrating a wider distribution for PA-VH/KN hydrogels with the mean shifted above 104 m2.
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FN, in promoting capillary-like network formation (43). Thus, the 
inclusion of bioactive peptides (PA-RGDS or PA-GHK) and pro-
teins in combination with 3D cocultures including hMSCs may fur-
ther support HUVEC behavior.
3D cocultures of cancer cells with stromal cells in PA/KN 
hydrogels promote intercellular network formation
The TME mediates important interactions between tumor and 
endothelial cells (12). To investigate the potential of PA-VH/KN 
hydrogels to support cell-cell interactions within a controlled micro-
environment, we conducted 3D tricultures of ovarian cancer cells 
together with HUVECs and hMSCs. Cell spreading was observed in 
PA-VH/KN hydrogels, which was not the case in 3D monocultures 
of HUVECs or hMSCs, suggesting a synergistic effect between the 
three cell types in 3D tricultures. Before in-depth analysis of the cell 
behavior in 3D tricultures, we first assessed the effect of the three 
different peptides PA-VH/PA-RGDS (10:1), PA-VH/PA-GHK 
(10:1), and PA-VH (1:0) and compared the extent of the F-actin 
networks. Therefore, all three cell types were encapsulated in 
PA-VH/KN, PA-VH/PA-RGDS/KN, and PA-VH/PA-GHK/KN 
hydrogels and F-actin stained using rhodamine-conjugated phalloidin 
(Figs. 1B and 5A). The immunofluorescent (IF) images were ana-
lyzed using AngioTool to calculate the area covered by the F-actin 
network (fig. S7A). A significant increase in F-actin network cover-
age was observed for PA-VH/PA-RGDS/KN (38 ± 7%) compared 
to PA-VH/KN (18 ± 6%) hydrogels (P < 0.05). On the other hand, 
PA-VH/PA-GHK/KN hydrogels did not yield a significant differ-
ence in F-actin network formation compared to PA-VH/KN or 
PA-VH/PA-RGDS/KN hydrogels due to high sample variability as 
a result of hydrogel instability and small sample range (n ≤ 3). Con-
versely, consistent results with smaller variability were obtained for 
PA-VH/PA-RGDS/KN hydrogels over a large sample range (n ≥ 6). 
When comparing the use of GHK to RGDS, cells grown within PA-
VH/PA-GHK/KN hydrogels exhibited a similar level of spreading 
compared to cells grown within PA-VH/PA-RGDS/KN. This may 
be because of the angiogenic potential of GHK (44). Considering 
the variability in results obtained with PA-VH/PA-GHK, the peptide 
mixture PA-VH/PA-RGDS was found most favorable. Consequently, 
we used PA-VH/PA-RGDS/KN with and without FN to evaluate 
cell behaviors in comparison to Matrigel (Fig. 1B).
Fig. 4. HUVEC seeding on top of Matrigel and PA/KN hydrogels. (A) Bright-field images of HUVECs seeded on top of Matrigel and PA-VH/PA-RGDS/KN hydrogels on 
days 1 and 5, with a seeding density of 1 × 105 cells per gel. (B) IF images of F-actin network (phalloidin/red) and nuclei (DAPI/blue) of HUVECs seeded on top of PA-VH/
PA-RGDS/KN hydrogels. Samples from Matrigel disintegrated during sample preparation. (C) Monolayer of HUVECs stained for CD31 (green), nuclei (DAPI/blue), and 
F-actin network (phalloidin/red) as a positive staining control. In addition, the control was used as references for the signal strength when analyzing the CD31 stain in the 
PA/KN hydrogels. (D) IF images of CD31 (green) and F-actin network (phalloidin/red) of HUVECs grown on top PA-VH/PA-RGDS/KN hydrogels on day 9. (E) Scanning 
electron microscopy images of HUVECs covering the PA-VH/PA-RGDS/KN hydrogel surface on day 5.
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First, we determined the cell proliferation in 3D tricultures in 
PA-VH/PA-RGDS/KN(/FN) hydrogels compared to Matrigel. On 
the basis of the metabolic activity, a similar cell proliferation was 
observed in both matrices (Fig. 5B; readout fluorescence values in 
fig. S7B). There was an initial decrease in metabolic activity on day 4, 
most likely as a result of minor HUVEC and hMSC death, followed 
by a steady increase in metabolic activity. While cells in the PA-VH/
PA-RGDS/KN(/FN) hydrogels showed an initial lower metabolic 
Fig. 5. Triencapsulation of ovarian cancer cells, HUVECs, and hMSCs in PA/KN hydrogels and Matrigel (ovarian cancer/HUVEC/hMSC ratio of 560:6000:600). 
(A) Quantification of F-actin network coverage as percentage area coverage for different PA/KN hydrogel combinations. (B) Metabolic activity of tricultures over time in 
PA-VH/PA-RGDS/KN/FN hydrogels and Matrigel (values normalized to day 1). (C) Live (green)/Dead (red) images of tricultures in PA-VH/PA-RGDS/KN hydrogels and Matrigel 
on days 1, 7, and 14. (D) IF staining of F-actin network (phalloidin/red) and nuclei (DAPI/blue) of tricultures grown in PA-VH/PA-RGDS/KN/FN hydrogels and Matrigel on 
days 1, 7, and 14. (E) IF staining for CD31 (green), F-actin network (phalloidin/red), and nuclei (DAPI/blue) in Matrigel on day 4. (F) IF staining for CD31 (green), F-actin network 
(phalloidin/red), and nuclei (DAPI/blue) in PA-VH/PA-RGDS/KN hydrogel on day 7 with a 3D volume reconstruction (right). (G) Still video images of cell proliferation and 
spreading in PA-VH/PA-RGDS/KN hydrogels from days 2 to 7 (HUVECs labeled with a green cell tracker, F-actin network with red phalloidin, and nuclei with blue DAPI).
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activity compared to Matrigel, no difference was observed from 
days 8 to 14. Whereas the cell monocultures in Matrigel were prone 
to gel fragmentation, the tricultures in Matrigel contracted in size 
over the 14 days. We speculate that this contractile behavior was due 
to the relatively high cell density in these cultures, increasing the 
number of cell-cell interactions.
Next, we compared spheroid formation in the 3D tricultures in 
PA-VH/PA-RGDS/KN(/FN) hydrogels and Matrigel to the spheroid 
data from the 3D monocultures (see the “Cell monocultures within 
PA/KN hydrogels generate tumor spheroids” section). In both 
matrices, we observed an immediate increase in spheroid formation 
and size compared to the monoculture counterparts, as detected by 
IF microscopy (Fig. 5, C and D; Live/Dead assay and bright-field 
images in fig. S7C). Comparing 3D mono- and tricultures within 
PA/KN hydrogels on day 14, we detected an increase in spheroid size 
in the tricultures (Fig. 5C versus Fig. 3B). Spheroid sizes observed in 
3D monocultures in PA-VH/KN on day 21 (discussed in the “Hydrogel 
formation and characterization at the nano- and macroscale” sec-
tion) were now observed by day 14 in the tricultures using PA-VH/
PA-RGDS/KN(/FN) hydrogels. This accelerated growth may be the 
result of enhanced intercellular interactions between the different 
cell types, which have been associated with spheroid growth (45). 
No significant difference was detected between PA-VH/PA-RGDS/
KN and PA-VH/PA-RGDS/KN/FN hydrogels on the basis of the 
fluorescent micrographs and proliferation data. We hypothesize that 
this may be a reflection of keratin-containing adhesion sequences 
that mask the effect of FN. However, to determine the influence of 
FN in our system, a more detailed analysis of the cell expression is 
required. Thus, on the basis of the comparative results without FN, 
our subsequent work focused on PA-VH/PA-RGDS/KN. Overall, 
we conclude that not only 3D tricultures in PA-VH/PA-RGDS/KN 
exhibit enhanced spheroid size and growth compared to 3D mono-
cultures but also they are comparable to Matrigel.
Having evaluated the changes in spheroid formation between 
3D tri- and monocultures, next we assessed the F-actin network for-
mation in our PA/KN hydrogels. As discussed, 3D tricultures in 
PA-VH/PA-RGDS/KN led to an extensive F-actin network formation, 
which was absent in our stromal cell monocultures (see the “Cell 
monocultures within PA/KN hydrogels generate tumor spheroids” 
section). Using IF images, we performed a detailed image analysis 
on our 3D tricultures to determine the origin of the F-actin networks 
within PA-VH/PA-RGDS/KN hydrogels. The presence of hMSCs 
was confirmed by staining for 𝛼-smooth muscle actin (𝛼-SMA), which 
was aligned with the F-actin network (fig. S8A). We hypothesize 
that the presence of the F-actin network corresponds to the begin-
ning of angiogenesis. To test this, we investigated the position of 
HUVECs within the hydrogels. Cells grown within PA-VH/PA-
RGDS/KN hydrogels and Matrigel were stained with CD31, 
phalloidin/F-actin and 4′,6-diamidino-2-phenylindole (DAPI)/nuclei 
(Fig. 5E and fig. S8B). CD31 was stained positive in both matrices; 
however, unspecific staining was observed in the tumor spheroids. 
Thus, from the immunostaining alone, the F-actin network cannot 
be interpreted as the beginning of angiogenesis from HUVEC 
spreading. However, from the IF images, we created pseudo-volume 
filled images (Fig. 5F and fig. S8C). These images revealed that F-actin 
networks were integrated between adjacent spheroids, confirming 
that intracellular interactions between stromal and cancer cells play 
a role in the increased spheroid size observed in 3D tricultures com-
pared to monocultures.
In a second attempt to elucidate the HUVEC behavior within the 
PA/KN hydrogel, we used a cell tracker dye to label HUVECs, al-
lowing cell position to be tracked in relation to cell spreading over 
14 days (Fig. 5G and fig. S8D). The image sequence confirmed that 
the F-actin network formation took place between days 2 and 7 
(Fig. 5G), with a decreasing network by day 14, when instead large 
spheroids were visible (fig. S8E). Analyzing the cell tracker staining, 
some of the HUVECs coincide with the F-actin network. However, 
the majority was outside the F-actin network, suggesting that it did 
not originate from HUVECs. Thus, further optimization of the 
hydrogel formulation is required to promote tumor angiogenesis 
within PA/KN hydrogels. However, the images demonstrate the con-
tinuous cell spreading as evident by the buildup of F-actin networks. 
In summary, our 3D tricultures promote intercellular interactions in 
PA/KN hydrogels, while highlighting the positive impact of stromal 
cells on spheroid size and growth rate.
Responses to treatment in spheroid-containing  
PA/KN hydrogels
We have demonstrated the consistent tumor spheroid formation in 
our PA/KN hydrogels, as well as the benefits and added accuracy in 
modeling the TME by incorporating different cell populations. We 
have shown the versatility of the PA/KN hydrogels by changing PA 
sequences and protein composition to tailor the model’s applicability 
to the ovarian TME. To assess the functionality of our hydrogels, we 
tested the responses of tumor spheroids grown in PA/KN hydrogels 
to three different treatments: the matrix metalloproteinase inhibitor 
and antiangiogenic agent GM6001 and the first-line chemothera-
peutics paclitaxel (TXL) and carboplatin (PLT) (Fig. 6A) (9, 31). The 
dosages used in this study for GM6001 (20 M), TXL (100 M), and 
PLT (100 M) are commonly used for in vitro drug testing (6, 9, 31) 
and thus allow comparison with previous studies. For the treatment 
studies, the fold change in metabolic activity was normalized to day 1 
to allow comparison between the different treatments. The readout 
values are in fig. S10.
Ovarian cancer cells were encapsulated in PA-VH/KN hydrogels 
and Matrigel and treated 1 day after encapsulation for 14 days, with 
treatment changes every 2 to 3 days (control hydrogels at day 1; 
fig. S9A). While GM6001 did not affect spheroid size and metabolic 
activity (fig. S9B), as reported previously (9), TXL and PLT prevent-
ed spheroid formation as detected by bright-field and fluorescence 
microscopy (Fig. 6, B and C). A small number of cancer cells were 
still present after 14 days of treatment, although with lower meta-
bolic activity compared to controls on day 1 (TXL, 0.70 ± 0.05; 
PLT, 0.61 ± 0.09; control, 1.70 ± 0.18; Fig. 6D). There was no differ-
ence in the response to both chemotherapeutics. When comparing 
the response in spheroid-containing Matrigel (Fig.  6E), TXL and 
PLT treatment appeared more effective than in PA-VH/KN hydro-
gels, with a very low metabolic activity observed at day 14 compared 
to day 1 (TXL, 0.38 ± 0.02; PLT, 0.40 ± 0.02; control, 2.60 ± 0.05). 
However, previous studies have shown that drug uptake within 
Matrigel is unrealistically high, resulting in uptake values similar to 
those in 2D cell cultures (38). Thus, we conclude that cellular re-
sponses in PA/KN hydrogels are more physiological than Matrigel.
To further explore the effect of treatment, we conducted a brief 
study using PA/KN tricultures. Our preliminary results indicated a 
similar behavior to that of 3D monocultures, with reduced metabolic 
activity upon TXL and PLT treatment, however, with minor effects 
of GM6001 (Fig. 6E and fig. S9D). Interference from GM6001 may 
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suggest inhibition of the network structures formed by HUVECs and 
hMSCs as previously reported (46). This aspect may be explored in 
future experiments. A follow-up study may also include the separa-
tion of multiple cell types after 3D culture for separate analysis to 
measure the effect of treatment. Within the scope of this study, the 
experiments with chemotherapeutics have shown the anticipated 
response in ovarian cancer cells.
DISCUSSION
There is a need to advance 3D cancer models to capture the key com-
ponents of the TME and to screen improved or personalized thera-
peutics. Supramolecular hydrogels offer an opportunity to replicate 
the nanofibrous features of the extracellular microenvironment as 
well as include desired signaling epitopes. These self-assembling 
systems can also be engineered to interact with and incorporate key 
ECM components. Here, we demonstrate that PA/protein coassem-
bling bioinks can model the TME of ovarian cancer to a level that is 
similar to, yet more controlled than, that provided by Matrigel.
Ovarian cancer spheroids were grown over 21 days and reached 
a similar cross-sectional size compared to previous studies (9). We 
did not observe a hypoxic core found in many spheroids or tumors. 
However, this phenomenon is only observed when the spheroids or 
tumor mass reaches a diameter of >200 m, at which point diffusion 
is inhibited, eventually leading to a hypoxic core (47). We have 
shown the PA/KN hydrogel’s compatibility with multiple cell types 
and ability to selectively modify the peptide sequences to optimize 
cellular responses. In 3D tricultures, tumor spheroids interacted with 
HUVECs and hMSCs as well as the hydrogel matrix and their pro-
liferation were enhanced. F-actin networks were formed throughout 
Fig. 6. Treatment study with TXL, PLT, and GM6001 using cells grown in PA-VH/KN hydrogels and Matrigel. (A) Schematic showing the experimental setup for the 
treatment studies. Ovarian cancer cells (OVCAR-4) were encapsulated at a density of 500 cells/l with treatment starting 1 day after encapsulation. (B) Bright-field images 
of the tumor spheroid sizes after 14 days for the control and three treatments. (C) IF images of the F-actin network (phalloidin/red) and nuclei (DAPI/blue) of tumor spheroids 
on day 14 for all treatment conditions. The IF images correspond to the bright-field images in (B). (D) Metabolic activity of cells grown in PA-VH/KN hydrogels for all 
treatments over 14 days (values normalized to day 1), measured using an almarBlue assay. (E) Metabolic activity of cells grown in Matrigel for all treatments over 14 days 
(values normalized to day 1), measured using an almarBlue assay. (F) Metabolic activity of tricultures (ovarian cancer cell/HUVEC/hMSC ratio of 560:6000:600) in PA/KN 
hydrogels for all treatments over 14 days (values normalized to day 1), measured using almarBlue assay.
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the hydrogel and intercalated between adjacent spheroids. The extent 
of network formation was enhanced by using the bioactive sequences 
RGDS and GHK. Many other sequences, for example, IKVAV and 
GFOGER (12), have been shown to specifically promote angiogenesis, 
which may be used instead of GHK. In addition, GFs, such as VEGF 
or FGF, may be entrapped within the fibrous network to allow slow 
release. We validated the PA/KN hydrogels using cytotoxic drugs, 
with cellular responses observed for all tested treatments.
In this study, we primarily assess the performance of the PA/KN 
hydrogel while comparing it with Matrigel, showing similar results 
in most of the performed experiments. In spheroid monocultures, 
Matrigel led to an increased proliferation compared to PA/KN 
hydrogels, which may result from Matrigel’s undefined composition 
of ECM proteins (primarily collagen, laminin, and proteoglycans) 
and GFs. However, the PA/KN hydrogels provide adaptability by 
permitting the inclusion of keratins that are found in ovarian cancer 
tissue (KRT32 and KRT82). In 3D tricultures, we did not detect a 
significant difference in proliferation between Matrigel and PA/KN 
hydrogels. Furthermore, the two materials exhibited comparative 
levels of intracellular networks. Major advantages of our PA/KN 
hydrogel over Matrigel is the possibility to improve reproducibility 
and minimize potential batch-to-batch variations, while providing 
an ECM-like nanofibrous network able to maintain comparative 
cell viability to the current gold standard, Matrigel. As a result, 
these hydrogels offer an exciting possibility for the design of 3D 
disease models.
Similarly, other studies assessing the advantages and disadvantages 
of using basement membrane–derived materials compared with 
synthetic materials have found that synthetic hydrogels offer more 
control, reproducibility, and versatility. For example, Bray et al. (11) 
reported comparative results between starPEG-heparin hydrogels 
and Matrigel, with the polymer hydrogels offering controlled me-
chanical properties, integrin-binding sequences, and quantity of 
GFs, which enabled testing of a range of therapeutics and inhibitors. 
Along with PEG-based hydrogels, gelatin methacryloyl (GelMA) 
has been used as a 3D ovarian cancer model. For example, 
Kaemmerer et al. (31) reported that GelMA supports tumor spheroid 
formation and sufficient porosity for treatment with anticancer 
drugs. These studies also highlight similar Matrigel limitations as 
we have reported here. Furthermore, by cross-comparing GelMA/
PEG versus Matrigel studies to our PA/KN hydrogel versus Matrigel 
study, we see that the PA/KN hydrogels yield comparative perform-
ance. For example, the tumor sizes observed in our tricultures match 
those in studies using PEG (11) and GelMA (12) within a similar time-
line (100 to 200 m in diameter after 14 days). Taubenberger et al. 
reported the formation of endothelial networks in PEG-heparin gels 
sustainable over 10 days grown in cocultures of HUVECs and MSCs. 
Moreover, they observed that the inclusion of pregrown tumors en-
hanced angiogenesis. Similarly, we observed that PA/KN hydrogels 
support endothelial network formation in cocultures of MSCs and 
ovarian cancer cells, albeit not sustainable for 10 days. Last, the ad-
vantages that the porosity of GelMA offers for drug treatment (31) 
are also present in our PA/KN hydrogels as shown in Fig. 6. While 
PEG- and GelMA-based models are established hydrogels used 
normally in 3D cancer models, PA/KN hydrogels offer additional 
benefits. For example, PA/KN hydrogels exhibit both a nanofibrous 
network that resembles that of the native ECM, which neither PEG-
based nor GelMA-based hydrogels recreate. Moreover, the peptide/
protein coassembly strategy reported here permits incorporation of 
naturally occurring proteins in a manner that enables them to play 
both a structural and a signaling role. This emulates the way these 
macromolecules function in the native ECM. Overall, these hybrid 
hydrogels enable the design of 3D matrixes with controlled of mo-
lecular composition, nanofibrous architecture, and the capacity to 
present both specific bioactive epitopes and macromolecules.
Some of the limitations of PA-based hydrogels are cost of material 
and scalability. However, peptide-based self-assembling hydrogels 
offer attractive opportunities for in vitro applications, which is evi-
denced by a number of recent commercially available materials. Ex-
amples include Biogelx, which is currently being used in 3D breast 
cancer models for screening of new drugs; PeptiGels from Manchester 
Biogel, which have been used for postendoscopic treatment; and 
PuraStat from 3D Matrix, which has been developed for hemostasis. 
While these systems demonstrate that peptide-based self-assembling 
hydrogels are viable products for 3D culture applications, Matrigel 
remains the material of choice. Our study demonstrates that self- 
assembling materials can be rationally coassembled with ECM macro-
molecules to improve molecular and structural complexity while 
maintaining a high degree of control. Hence, it is possible to easily 
explore more complex hydrogels in a systematic manner, enabling 
the design of 3D microenvironments with high molecular diversity 
and reproducibility.
It is important to mention that the PA/KN coassembling system 
can be easily integrated with 3D bioprinting to provide macroscale 
precision and reproducibility (22). Bioprinting has already been ex-
plored to build 3D cancer models (48, 49). However, the nanofibrous 
network and the selective presentation of bioactive epitopes are 
unique properties to self-assembling materials and are known to 
directly affect cell behavior. While 3D bioprinting was not used in 
this study, the potential of the system to be used as a bioink offers 
additional opportunities for building more complex, yet controlled 
and reproducible, 3D cancer models (50). Nonetheless, in this study, 
we have demonstrated the possibility to use our PA/KN system to 
engineer an innovative 3D ovarian cancer model with a high degree 
of molecular versatility and tunability, enabling more effective test-
ing of anticancer therapeutics.
METHODS
PAs (synthesis and purification)
PA-H (purity, 97.8%), PA-VH (purity, 98.9%), PA-GHK (purity, 
99.5%), and PA-RGDS (purity, 99.2%) were synthesized in-house 
(fig. S1) as previously described (22). Additional PA-H (purity, 98.1%) 
was purchased from Biomatik (ON, Canada). In-house synthesis was 
carried out using an automatic microwave assisted solid-phase peptide 
synthesizer (SPPS) (CEM Liberty Blue) using 4-methylbenzhydrylamine 
Rink amide resin (0.52 mmol/g, Novabiochem Corporation, UK) with 
the tail coupled subsequently. Purification of all peptides was car-
ried out through reverse-phase high-performance liquid chroma-
tography (HPLC) using a 2545 Binary Gradient Preparative HPLC 
(Waters 2767, Waters, USA), a C18 column (Atlantis Prep OBD T3 
Column, Waters, USA) and a gradient of 2 to 100% acetonitrile in 
water [0.1% (v/v) trifluoroacetic acid] over 40 min. Detection was 
carried out concomitantly with 2489 UV/Vis and an electrospray 
ionization mass spectrometer (ESI-MS) detector (Waters, USA). 
Peptide purity was determined by analytical HPLC as well as ESI-
MS (Thermo LXQ, Thermo Fisher Scientific, USA). Purity ≥95% 
was accepted suitable for usage. Peptides were freeze-dried to yield 
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lyophilized powder. Peptide solutions were prepared using 10 mM 
HEPES, (pH 7.5).
Matrigel
Matrigel (Corning Matrigel Growth Factor Reduced Basement Membrane 
Matrix, LDEV-Free) was purchased from Scientific Laboratory Supplies 
(catalog no. 356230). To minimize the potential influence of batch-
to-batch variations of Matrigel, only one batch of Matrigel was used 
for this study (LOT 7202001).
Proteins
Keratin was extracted from human hair and freeze-dried using a 
modified protocol (51), which yields mainly in intact hair keratin. 
Bovine-derived FN was purchased from R&D Systems (1030-FN) 
provided as 1 mg/ml in a 400 mM urea, 500 mM NaCl, and 50 mM 
tris-HCl solution (pH 7.5). Peptide solutions were prepared using 
10 mM HEPES, (pH 7.5).
Zeta potential
Samples (n = 3 per condition) were prepared at a concentration of 1 mg/ml 
in 10 mM HEPES and filtered before measuring on a Malvern 
Nano ZS series Zetasizer, with each measurement repeated three times.
Circular dichroism
The experiments were run at concentration 0.1 mg/ml in 10 mM 
HEPES buffer for both PA and keratin. Measurements were carried 
out at 25°C using a 0.1-cm–path length and 300-l-volume cuvette 
(Chirascan, Applied Photophysics, UK). Three scans were run per 
sample and at least three independent repeats per sample condition 
(n ≥ 3). The data were normalized to the baseline (blank control; 
10 mM HEPES buffer) and the averaged trace smoothed to reduce 
noise without causing spectrum distortion. The data manipulation 
was carried out using the Chircascan trace manipulation software.
Transmission electron microscopy
Samples were prepared at a concentration of 0.01 mg/ml in 10 mM 
HEPES. Carbon copper grids (Agar Scientific, Stansted, UK) were 
used to mount the samples. Excess was removed using filter paper 
before incubation with 2% filtered uranyl acetate solution for 30 s. 
Grids were then washed with ultrapure water for 30 s, air-dried for 
24 hours at room temperature (RT) and imaged using a JEOL 1230 
transmission electron microscope operated at an acceleration voltage 
of 80 kV. All the images were recorded by a Morada charge-coupled 
device camera (Image Systems). At least 10 images were taken in 
random locations per condition.
Degradation study
Hydrogels were formed using PA-VH and PA-H by injecting 30 l 
of PA into 70 l of KN, incubated over 4 hours before being trans-
ferred into vials filled with PBS or 10 mM HEPES. Hydrogels were 
kept in excess buffer (PBS or HEPES) to prevent false negatives as a 
result of dehydration. At predefined time points (daily in the first 
week, then biweekly; PBS, n = 6 per time point; 10 mM HEPES, n = 4 
per time point), the solution was removed from the vial and the vial 
with hydrogel weighed. Liquid removal was removed with a pipette 
and a small cotton swab. After 3 months, the final vial with hydrogel 
weight was recorded, and the vial was cleaned and weighed. Mass 
loss was calculated as “M0 − MTime point/M0,” where M0 is the weight 
at day zero minus the weight of the vial.
Rheology
Hydrogels were prepared as 30 l of PA in 70 l of KN and formed 
for 4 hours at RT before being transferred to a 10 mM HEPES (n ≥ 6) 
solution or medium [Dulbecco’s Modified Eagle’s Medium (DMEM); 
n ≥ 3] and subsequently stored overnight before measurement. Sam-
ples were analyzed using a Discovery Hybrid Rheometer (DHR-3, 
TA Instruments, USA) equipped with an 8-mm-diameter parallel 
plate geometry. Rheological characteristics were monitored by am-
plitude sweep and frequency sweep. G′ (storage modulus) and G″ 
(loss modulus) were measured at 25°C and at a constant frequency 
of 1 Hz in the 0.01 to 10% strain during the amplitude sweep, while 
the oscillation frequency experiments were carried out at a 0.1% fixed 
strain along 0.1 to 100 Hz.
Scanning electron microscopy
Samples were fixed using 4% PFA solution for 2 hours at RT. Then, 
the samples were dehydrated from a 100% water solution to a 100% 
ethanol solution in serial steps and dried using a critical point drier, 
K850 (Quorum Technologies), exchanging the ethanol for carbon 
dioxide. Carbon black tape was used to adhere the samples to 
metal stubs. Before imaging, samples were cut open to reveal the 
inside of the hydrogel, gold coated for 30 to 45 s, and imaged on a 
FEI Inspect F.
Cell culture
Human epithelial ovarian cancer cells (NIH:OVCAR-4) and hMSCs 
(PromoCell C-12974 hMSC-BM-c) were maintained in DMEM 
(4.5 g/liter d-glucose) with GlutaMAX, supplemented with 1% 
penicillin-streptomycin (P/S) and 10% fetal bovine serum (FBS). 
HUVECs were purchased from PromoCell (pooled donors, C-12203) 
and grown in endothelial cell growth medium (C-22010; PromoCell). 
HUVECs and hMSCs were used at passage 2 (P2) to passage 7 (P7) 
and NIH:OvCar-4 at < P20. Monocultures were placed in DMEM 
supplemented with 1% P/S and 10% FBS. Tricultures were placed in 
endothelial cell growth medium, supplemented with VEGF (2 ng/ml). 
Treatments were carried out using DMEM without P/S and FBS.
2D cell cultures
For cell seeding experiments with HUVECs, a density 10,000 cells 
per gel was used. The cells were suspended in cell media and added 
to a well plate with preformed hydrogels (Matrigel or PA/KN 
hydrogels). In the case of PA/KN gels, HUVECs were suspended 
in a KN solution (10 mg/ml), and 70 l of the KN/cell solution 
(~140 cells/l) was added per well in a 96-well plate. Subsequently, 
15 l of PA was injected into the KN/cell solution and incubated 
for 30 min at 37°C on a shaker. One-day post-seeding hydrogels 
were transferred into a 48-well plate. In the case of Matrigel, the 
HUVECs were suspended in media and added to the preformed 
gels (10,000 cells per gel) and incubated for 30 min at 37°C on a 
shaker. One-day post-seeding hydrogels were transferred into a 
48-well plate.
3D cell cultures
For cell encapsulation, lyophilized PA and proteins were treated with 
ultraviolet light for 30 min before dissolving in 10 mM HEPES at a 
concentration of 10 mg/ml. Cells were suspended in PA solution or 
Matrigel using the following cell densities:
• Stromal cell viability: 1000 HUVECs/l and 600 hMSCs/l, 
respectively.
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• HUVEC encapsulation study: 1000 cells/l.
• Monoculture: 500 OVCAR-4/l.
• Triculture: 6000 HUVECs/l, 600 hMSCs/l, and 560 OVCAR-4/l.
Polydimethylsiloxane (PDMS) squares were prepared in petri 
dishes (PDMS precut and autoclaved before use), and 45 l of pro-
tein solution was pipetted onto each PDMS square. Subsequently, 
15 l of PA (with/without cells) was injected into the protein droplet. 
Hydrogels were formed for 30 min at RT prior and transferred into 
a 48-well plate with culture medium. Peptide sequences were used 
as PA-H or PA-VH (10 mg/ml) or in combination 10:1 with either 
PA-GHK or PA-RGDS (10 mg/ml), i.e., 10 l of PA-RGDS or PA-
GHK (10 mg/ml) per 100 l of PA-VH (10 mg/ml). KN was used at 
a concentration of 10 mg/ml either alone or with addition of FN 
(1 mg/ml) at 100 l FN per 900 l of KN. As controls, undiluted 
Matrigel (GF reduced; Corning) was mixed with cells, and 15 l was 
pipetted onto each PDMS square. Samples were incubated for 30 min 
at 37°C and transferred into a 48-well plate with culture medium. 
All 3D cell culture experiments were performed in biological repli-
cates with at least triplicate samples.
alamarBlue and Live/Dead assays
alamarBlue reagent was used at a concentration of 700 l in 10-ml 
medium (7%). Therefore, culture medium was removed, and 300 l 
of alamarBlue solution was added and incubated for 6 hours including 
three control samples. Subsequently, fluorescent signals of 100-l 
samples were measured in triplicate on a FLUOstar OPTIMA (BMG 
Laboratory) plate reader (excitation, 544 nm; emission, 590 nm) us-
ing a black 96-well plate. Media without cell-laden hydrogels with 
alamarBlue reagent served as negative control for background read-
ing. The signal of pure media (no alamarBlue) was subtracted from 
all samples. Subsequently, the readout values were divided by the 
background reading (Media + alamarBlue + no cells), following the 
simplified calculation from Thermo Fisher Scientific. The corrected 
fluorescent signals were normalized to day 1. The uncorrected val-
ues can be found in the Supplementary Materials (figs. S5C, S7B, 
and S10). For Live/Dead staining, 2-l ethidium homodimer-1 (2 
mM) and 1-l calcein AM (4 mM) were added to 1 ml of culture 
medium, and samples were imaged after 15 min using a confocal 
microscope. A monolayer was used as a control to check the Live/
Dead staining.
Immunohistochemistry
Slides of normal and cancerous ovarian tissue were prepared as serial 
formalin-fixed paraffin-embedded tissue sections (5 m). Sections 
were deparaffinized in xylene and rehydrated in dilutions of ethanol 
and water. Antigen retrieval was performed using 1× citrate-based 
solution (pH 6; H-3300; Vector Laboratories) at 95°C for 10 min. Then, 
sections were washed with 1× tris-buffered saline–Tween (TBS-T), 
blocked with 5% bovine serum albumin (BSA)/PBS for 1 hour. at RT 
and treated with 3% H2O2. Antibodies (KRT32 ABIN517410 and 
KRT82 ABIN651240; Antibodies-online) were diluted 1:50 in 5% BSA/
PBS and incubated overnight at 4°C, followed by biotinylated goat 
anti-mouse immunoglobulin G (BA-9200; Vector Laboratories) at 1:200 
in 5% BSA/PBS for 45 min. Samples were washed with 1× TBS-T and 
stained using an ABC HRP Elite kit (PK-6100-NB; Vectastain) and 
hematoxylin (GHS116; Sigma-Aldrich), mounted, and imaged using 
a NanoZoomer S210 (Hamamatsu). Staining controls without the pri-
mary antibody, as well as without primary and secondary, were included 
for all experiments. Examples of the controls for no primary are in fig. S2.
IF staining and confocal microscopy
DAPI (D1306) and rhodamine phalloidin (R415) were purchased 
from Sigma-Aldrich. Primary (CD31 ab32457, 𝛼-SMA ab7817, KRT32 
ABIN517410, and KRT82 ABIN651240) and secondary (Alexa Fluor 
488/555/568/594) antibodies were purchased from Abcam, Antibodies- 
online, and Life Technologies, respectively. Samples were fixed in 
4% PFA/PBS for 2 hours, permeabilized in 0.2% Triton X-100/PBS 
for 2 hours and blocked in 2% BSA/PBS overnight at RT. Primary 
antibodies were diluted 1:100 in 2% BSA/PBS and incubated for 
48 hours at 4°C. Secondary antibodies were diluted 1:1000 in 2% BSA/
PBS and incubated overnight at 4°C. An Alexa Fluor 488–conjugated 
antibody (303110, BioLegend) was used at 1:100 in 2% BSA/PBS 
overnight at 4°C. DAPI and rhodamine phalloidin were diluted 1:500 
and 1:250, respectively, in PBS and incubated for 2 hours at RT. 
Samples were washed with PBS between each step. A green cell 
tracker dye (CMFDA C2925; Life Technologies) was also used to 
label HUVECs by adding 4 mM to the cell suspension for 30 min 
before cell encapsulation into the hydrogels. Fluorescent images were 
acquired using Leica TCS SP2 and Zeiss LSM710 confocal micro-
scopes. Samples were imaged acquiring z-stacks ranging from 5 to 
20 m depending on the sample size. The PA/KN hydrogels were 
checked for autofluorescence before staining. In addition, bright-
field images were taken of PA hydrogels without cells after 21 days 
of incubation.
Image analysis
ImageJ (version l.52i) was used to compile z-stacks and adjust colors. 
AngioTool (version 0.5a) was used the measure the density of F-actin 
networks (fig. S7A). Imaris (version x64 9.2.1) was used to create 
3D videos of the z-stacks and volume images. Spheroid cross-sectional 
area was calculated using ImageJ, with cutoff points for days 1 and 
4 at 100 m2 and for days 7 and 14 at 300 m2.
Treatment with cytotoxic drugs and inhibitor
3D cell monocultures were treated on day 1 using GM6001 
(20 M), TXL (100 M), and PLT (100 M). Treatment solutions 
were prepared in DMEM without supplements and exchanged every 
2 to 3 days. As controls, medium changes were performed without 
treatment.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 (ver-
sion 8.0.2). One-way analysis of variance for multiple comparisons 
was used. Nonparametric statistics were used when the samples did 
not present a normal distribution (Mann-Whitney test). Statistical 
significance was set to P < 0.05 (*P < 0.05; **P < 0.01; ***P < 0.001).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/40/eabb3298/DC1
View/request a protocol for this paper from Bio-protocol.
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